← board
ABEO
Abeona Therapeutics, Incdistress 1/10 · well-funded / low risk$6.38-1%today-12% from 52w high
Lead: RDEB
Revenue
pre-revenue
Liquidity
$168M
Runway
2.2 yrs
Shares 1y
+11%
Price & events
+19.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-9.1%
1W
+11.5%
1M
+15.6%
3M
+23.6%
6M
-4.9%
1Y
+24.4%
2Y
-80.5%
5Y
-84.9%
All
Overview
- Market Cap
- $363.63M
- Enterprise Value
- $307.01M
- Volume
- 97.19K
- 52 Week Range
- $4.17 – $7.29
- Total Shares
- 57.00M
- Float Shares
- 36.62M
- Short %
- 25.77%
- % Held by Insiders
- 16.59%
- % Held by Institutions
- 70.37%
- RVOL
- 0.07x
- Beta
- 1.33
Pipeline stages · 1 programs
EB-101 Surgical application of RDEB wounds
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-30 | Phase 3 | EB-101 Surgical application of RDEB wounds | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB | 12 | active not recruiting |
Catalyst news & presentations · 6
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)ABO-701 · IND submission for ABO-701SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- Q3 2025trial initiationsecondaryZEVASKYN · Anticipated first patient treatment.SEC 8-K
- 2025-06-27partnershipZEVASKYN · Completed sale of Rare Pediatric Disease PRV for $155M gross proceeds.SEC 8-K
- April 29, 2025PDUFAPDUFApz-cel · PDUFA target action date for BLA resubmissionSEC 8-K
- October 29, 2024regulatory submissionFiled (NDA/BLA)pz-cel · Completed BLA resubmission to FDA for pz-celSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+209% upside) · 7 analysts
- 2026-05-28HC Wainwright & Co.Buy
- 2026-03-19HC Wainwright & Co.Buy
- 2026-03-10HC Wainwright & Co.Buy
- 2025-10-13HC Wainwright & Co.Buy
- 2025-08-18HC Wainwright & Co.Buy
- 2025-08-15OppenheimerOutperform
Competitors — RDEB
- INMBInmune Bio, Inc.$47M · D5
Recent news
- 2026-07-22Abeona Therapeutics (ABEO) CFO has shares withheld to cover taxes - Stock Titan
- 2026-07-21Abeona Therapeutics (ABEO) Expands Zevaskyn Access with New Trea - GuruFocus
- 2026-07-21Abeona Therapeutics (ABEO) Expands Zevaskyn Access with New Trea - GuruFocus
- 2026-07-21Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN® - GlobeNewswire
- 2026-07-13Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones - Stock Traders Daily
- 2026-07-13Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones - Stock Traders Daily
- 2026-07-10Form 4 Abeona Therapeutics Inc For: 9 July By Investing.com - Investing.com UK
- 2026-07-10Abeona Therapeutics (NASDAQ: ABEO) shifts 760,870 warrants to SILV Fund - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.